PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements

Key Takeaways PODD secured FDA clearance for Omnipod 5 enhancements, including a 100 mg/dL Target Glucose option. PODD's updated algorithm aims to improve automated insulin delivery and reduce interruptions for users. Insulet shares gained 2.7% after the news, supported by ongoing expansion of the Omnipod 5 platform. Insulet Corporation (PODD) recently received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a ...